Breitner J C S, Haneuse S J P A, Walker R, Dublin S, Crane P K, Gray S L, Larson E B
Geriatric Research Education and Clinical Center, Department of Veterans Affairs Medical Center, VA Puget Sound Health Care System, Seattle, WA 98108, USA.
Neurology. 2009 Jun 2;72(22):1899-905. doi: 10.1212/WNL.0b013e3181a18691. Epub 2009 Apr 22.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent Alzheimer dementia (AD).
We analyzed the association of prior NSAID exposure with incident dementia and AD in the Adult Changes in Thought population-based cohort aged > or = 65 years (median 74.8) at enrollment. Participants were members of Group Health, which provided computerized pharmacy dispensing records from 1977 onward. We studied 2,736 dementia-free enrollees with extensive prior pharmacy data, following them biennially for up to 12 years to identify dementia and AD. Cox proportional hazards regression assessed association of dementia or AD with NSAID use graded in standard daily doses (SDD) dispensed over 2 years (e.g., heavy use = 500 + SDD), with some analyses also adding consecutive biennial self-reports of NSAID use.
Pharmacy records identified 351 participants (12.8%) with history of heavy NSAID use at enrollment. Another 107 became heavy users during follow-up. Some 476 individuals developed incident dementia, 356 with AD (median onset ages 83.5 and 83.8 years). Contrary to the hypothesis that NSAIDs protect against AD, pharmacy-defined heavy NSAID users showed increased incidence of dementia and AD, with adjusted hazard ratios of 1.66 (95% confidence interval, 1.24-2.24) and 1.57 (95% confidence interval, 1.10-2.23). Addition of self-reported exposure data did not alter these results.
These findings differ from those of other studies with younger cohorts. The results observed elsewhere may reflect delayed onset of Alzheimer dementia (AD) in nonsteroidal anti-inflammatory drug (NSAID) users. Conceivably, such delay could result in increased AD incidence in late old age. The relation of NSAID use and AD pathogenesis needs further investigation.
非甾体抗炎药(NSAIDs)可能预防阿尔茨海默病(AD)。
我们在入组时年龄≥65岁(中位年龄74.8岁)的基于人群的成人思维变化队列中,分析既往NSAIDs暴露与新发痴呆及AD之间的关联。参与者为健康集团成员,该集团提供了自1977年起的计算机化药房配药记录。我们研究了2736名无痴呆的入组者,他们有丰富的既往药房数据,每两年对其随访长达12年以确定痴呆和AD。Cox比例风险回归评估痴呆或AD与按2年配药的标准日剂量(SDD)分级的NSAIDs使用之间的关联(例如,大量使用=500+SDD),一些分析还增加了NSAIDs使用的连续两年自我报告。
药房记录显示351名参与者(12.8%)在入组时有大量NSAIDs使用史。另外107人在随访期间成为大量使用者。约476人发生新发痴呆,356人患AD(中位发病年龄分别为83.5岁和83.8岁)。与NSAIDs预防AD的假设相反,药房定义的大量NSAIDs使用者痴呆和AD的发病率增加,调整后的风险比分别为1.66(95%置信区间,1.24 - 2.24)和1.57(95%置信区间,1.10 - 2.23)。加入自我报告的暴露数据并未改变这些结果。
这些发现与其他针对年轻队列的研究结果不同。在其他地方观察到的结果可能反映了非甾体抗炎药(NSAIDs)使用者中阿尔茨海默病(AD)发病的延迟。可以想象,这种延迟可能导致老年后期AD发病率增加。NSAIDs使用与AD发病机制之间的关系需要进一步研究。